Alkermes PLC (ALKS) reports over $1.5 billion in revenue, retires all debt, and outlines strategic plans for 2025 amidst ...

ALKS reports better-than-expected fourth-quarter 2024 results. Net sales of proprietary products increase year over year. Shares rise.

For 2025, Alkermes plans to generate over $200 million in EBITDA while advancing its orexin program, particularly ALKS 2680, which is enrolling Phase 2 studies for narcolepsy. These studies are ...

TD Cowen analyst Joseph Thome raised the firm’s price target on Alkermes (ALKS) to $38 from $35. The firm said total Q4 revenue came in above ...

Alkermes reported strong earnings by exceeding both revenue and earnings expectations in its latest quarterly release.

Beyond analysts' top -and-bottom-line estimates for Alkermes (ALKS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the ...

Others jostling for market share include Alkermes' Aristada (aripiprazole lauroxil), which is administered every six or eight weeks. The CRL is a setback to Teva as it tries to rebuild its ...

Aripiprazole is a generic prescription drug used to treat certain mental health conditions. It’s also available as the brand-name drug Abilify. Aripiprazole can cause side effects that range ...

Alkermes Plc (NASDAQ:ALKS) reported strong financial results for the fourth quarter of 2024, surpassing earnings per share (EPS) and revenue forecasts. The company's EPS stood at $1.05, significantly ...